Sorrell v. IMS Health Inc.
The Court struck down a Vermont law that barred pharmacies from selling doctors' prescription records to data-mining firms used by drug companies for marketing, ruling that the law singled out marketing speech and pharmaceutical marketers for disfavored treatment.
Because the law let the same prescriber data flow freely for almost any other purpose while blocking only drug-company marketing uses, the Court held it triggered heightened First Amendment scrutiny and could not survive it, reinforcing strong constitutional protection for commercial speech even when a state's motives are to protect privacy or public health.
“Speech in aid of pharmaceutical marketing, however, is a form of expression protected by the Free Speech Clause of the First Amendment.”
The majority's starting premise that drug marketing speech receives First Amendment protection.
How it got here: A federal trial court upheld Vermont's law; the Second Circuit reversed on First Amendment grounds; Vermont asked the Supreme Court to review that reversal.
The Case in Depth
What happened
Drug companies use "detailing" — sales visits to doctors — often relying on data about a doctor's past prescriptions bought from data-mining firms, which get the information from pharmacies. Vermont passed a law barring pharmacies from selling or letting that prescriber data be used for marketing unless the doctor consented, though the data could still be shared for many other purposes. Data miners and a drug-manufacturer trade group sued, arguing the law violated their free-speech rights.
The question before the Court
Could Vermont stop pharmacies from selling doctors' prescription records to data companies that helped drug companies target their sales pitches?
The Court's answer
No — the Court ruled that Vermont could not bar pharmacies from selling or using doctors' prescription records for drug-marketing purposes while letting the same data flow freely for almost every other use. Because the law singled out marketing speech and pharmaceutical marketers for disfavored treatment, it triggered heightened First Amendment scrutiny, the toughest standard the Court applies short of an outright ban.
Vermont's stated goals — protecting doctors' privacy and controlling health costs — did not save the law, since it allowed nearly unlimited other uses of the same data and ultimately aimed to prevent marketing from persuading doctors, which the Court said is not a valid reason to restrict truthful speech. The Second Circuit's decision striking down the law was affirmed.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Pharmaceutical companies and data-mining firms can keep buying and using doctors' prescribing records to fine-tune sales pitches, at least absent a more neutral privacy law. States seeking to regulate how commercial information is used for marketing must now write narrower, more evenhanded rules or risk running afoul of the First Amendment's protection for commercial speech.
What changes now
This is a final merits decision, not a temporary order. The Second Circuit's judgment blocking enforcement of Vermont's law stands, and pharmacies, data miners, and drug companies in Vermont may resume using prescriber-identifying data for marketing as before. Other states with similar restrictions on marketing uses of prescription data face renewed First Amendment challenges under this ruling's heightened-scrutiny framework.
What this does not decide
The Court did not decide that all privacy or health-cost regulations affecting speech are unconstitutional, nor that prescriber data must always be treated as ordinary commercial speech. It left open whether a more narrowly drawn, evenhanded privacy law restricting sale or disclosure of prescriber data in only limited circumstances might survive review.
Concurrences and dissents
How the Justices voted
Majority (6). Justice Kennedy (author), joined by Justice Roberts, Justice Scalia, Justice Thomas, Justice Alito, and Justice Sotomayor.
Dissent (3). Justice Breyer (author), joined by Justice Ginsburg and Justice Kagan.
Dissent — Justice Breyer
Justice Breyer argued the Court should have reviewed Vermont's law under a deferential standard for ordinary economic regulation rather than heightened First Amendment scrutiny, since the law only withheld data used to craft sales pitches and did not ban or compel any speech. He contended the statute easily satisfied even the stricter commercial-speech test because it served substantial, speech-neutral interests in privacy, cost containment, and unbiased prescribing information, with only modest harm to speech and no better alternative available. Read the full dissent →
How the Court got there
The legal reasoning, step by step
- The Court first asked whether Vermont's law was content-based and speaker-based, meaning it treated speech differently depending on its subject matter and who was speaking. It found the law let prescriber data flow for almost any use except marketing, and barred only pharmaceutical marketers — not other buyers — from using it, which triggered heightened judicial scrutiny, a demanding level of review requiring a strong justification.
- The Court rejected Vermont's argument that this was just an ordinary economic regulation with only incidental effects on speech, holding that creating and disseminating information is itself speech protected by the First Amendment, so a targeted restriction on using that information for marketing is a real speech burden, not a side effect of regulating commerce.
- The Court distinguished a prior case involving restricted access to government-held arrest records, explaining that Vermont's law restricted information already in private hands and directly burdened the speech of the parties suing, unlike the earlier case where the challengers had no personal free-speech stake.
- Applying the government's burden to justify a content-based speech restriction, the Court found Vermont's privacy rationale unconvincing because the law let prescriber data be shared broadly for nearly every purpose except marketing, so it was not actually designed to protect confidentiality.
- The Court also rejected Vermont's public-health and cost-saving rationale, holding that a government may not restrict truthful speech simply because it fears that persuasive marketing will lead listeners — here, doctors — to make choices the government disfavors.
- Concluding that Vermont's justifications amounted to disagreement with the message pharmaceutical marketers were conveying rather than a neutral, adequately tailored interest, the Court found the law could not survive heightened scrutiny under either a commercial-speech test or a stricter standard.
Doctrinal impact
Cases affected by this decision
Distinguishes Los Angeles Police Dept. v. United Reporting Publishing Corp. (528 U. S. 32)
The Court said this case did not control because Vermont restricted privately held data and burdened the challengers' own speech.